Check for updates

OPEN ACCESS

EDITED BY Masashi Tanaka, Health Science University, Japan

REVIEWED BY Pasquale Mone, University of Molise, Italy Toshiaki Seko, Hokkaido Chitose College of Rehabilitation,

Japan *CORRESPONDENCE Konghe Hu Mhgksq@126.com

[†]These authors share first authorship

RECEIVED 27 May 2024 ACCEPTED 05 August 2024 PUBLISHED 23 August 2024

CITATION

Lai T, Guan F, Chen Y and Hu K (2024) Cross-sectional comparison of the association between three different insulin resistance surrogates and frailty: NHANES 1999-2018. *Front. Endocrinol.* 15:1439326. doi: 10.3389/fendo.2024.1439326

COPYRIGHT

© 2024 Lai, Guan, Chen and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cross-sectional comparison of the association between three different insulin resistance surrogates and frailty: NHANES 1999-2018

Tianjie Lai^{1†}, Fenglei Guan^{2†}, Yunxian Chen² and Konghe Hu ^{1*}

¹Department of Spine Surgery, The Affiliated Yuebei People's Hospital of Shantou University Medical College, Shaoguan, Guangdong, China, ²Department of Cardiology, The Affiliated Yuebei People's Hospital of Shantou University Medical College, Shaoguan, Guangdong, China

Background: The correlation between various insulin resistance surrogates and frailty remains under investigation in the scientific community.

Methods: Data from NHANES (1999-2018) were used. We utilized weighted binary logistic regression, trend tests, RCS analysis, and subgroup analysis to comprehensively assess the link between METS-IR, HOMA-IR, and TyG, and frailty risk.

Results: The results revealed a significant positive association between high levels of METS-IR, HOMA-IR, and TyG with the risk of frailty in all models. Notably, in model 4, the highest quintile of METS-IR showed the strongest link (OR: 2.960, 95% CI: 2.219-3.949), with HOMA-IR (OR: 2.522, 95% CI: 1.927-3.301) following closely behind. Trend tests revealed a positive trend between METS-IR, HOMA-IR, and TyG with the risk of frailty (P for trend < 0.05). RCS analysis showed a linear relationship between METS-IR and the risk of frailty (P for nonlinearity > 0.05). In contrast, HOMA-IR and TyG exhibited a U-shaped nonlinear relationship (P for nonlinearity < 0.05).

Conclusion: The research identified a linear association between METS-IR and frailty risk, whereas HOMA-IR and TyG displayed a U-shaped, nonlinear relationship pattern with the risk of frailty. Among the varying levels examined, the linkage between METS-IR and frailty was most pronounced in the top quintile.

KEYWORDS

insulin resistance surrogates, frailty, TyG, METS-IR, HOMA-IR, NHANES

Abbreviations: FI, Frailty Index; FFP, Fried Frailty Phenotype; FRAIL, Frailty Questionnaire; IR, Insulin Resistance; TyG, Triglyceride-glucose Index; METS-IR, Metabolic Score for Insulin Resistance; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; NHANES, National Health and Nutrition Examination Survey; RCS, Restricted Cubic Spline; OR, Odds Ratio; Cis, Confidence Intervals; SGLT2, Sodium-dependent Glucose Transporters 2; CAD, Coronary Artery Disease.

10.3389/fendo.2024.1439326

1 Introduction

The term "frailty" was once considered synonymous with disability, frequently linked with advanced age and various underlying conditions. However, with the progression of research, an increasing number of scholars recognize that frailty is a biological syndrome resulting from the decline of multiple physiological systems. It indicates a decrease in the body's normal physiological reserves and resistance to stressors, causing individuals to face worse-than-expected outcomes compared to those with normal physical conditions (1, 2). Although frailty is typically defined as a common syndrome in the elderly, recent studies have increasingly shown that middle-aged and even young adults may also exhibit similar frailty symptoms (3). These symptoms may be associated with various background factors such as lifestyle, socioeconomic status, and health behaviors (4). A community study showed that the prevalence of frailty in the community is about 6.9%, and this rate increases with age (1). Frailty develops relatively slowly, particularly in its early stages (5). However, the definition of frailty is considered to also apply to younger individuals with physical frailty, but most current intervention trials mainly involve older populations, thus frailty in younger individuals has not received adequate attention (6). Given the negative impact of functional decline associated with frailty, early identification and prevention of frailty progression are essential (7). However, there is no clear gold standard for diagnosing frailty. Its common characteristics include unintentional weight loss, impaired physical function, feelings of weakness, fatigue, and low levels of physical activity levels. Currently, tools for assessing frailty include the Fried Frailty Phenotype (FFP) (1), the Frailty Index (FI) (8), and the Frailty Questionnaire (FRAIL) (9). Among these tools, the FI has widespread application value in assessing the characteristics of frail populations. By comprehensively considering multiple physiological and cognitive indicators, the FI can more fully reflect an individual's level of frailty (10).


Insulin resistance (IR) refers to the decreased or impaired insulin sensitivity of target organs or tissues, resulting in a reduced efficiency of insulin-stimulated glucose utilization. IR frequently causes vascular changes and impairs organ functionality, and is regarded as a fundamental basis for many diseases. RI and diabetes are exhibiting a trend of early onset, and recognizing insulin resistance can aid in identifying early declines in bodily capabilities. However, the euglycemic-hyperinsulinemic clamp, the gold standard for evaluating IR, is not widely utilized because of its complexity and invasive nature. Consequently, numerous alternative indicators of IR have been developed, such as the Triglyceride-Glucose Index (TyG), Metabolic Score for Insulin Resistance (METS-IR), and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Most of these indicators reflect the body's glucose metabolism by blood glucose and lipid levels. Due to their ease of acquisition and simple calculation, they have shown certain advantages in studies of diseases such as coronary heart disease and hypertension (11). However, the relationship between insulin resistance, which is a foundation for cardiovascular diseases and aging, and frailty has not been widely studied. We aim to explore the association between insulin resistance and frailty, as defined by the FI index, using different IR substitutes in the general population and to compare their predictive abilities.

As far as we know, we are the first to conduct a cross-sectional comparison of the relationship between different insulin resistance surrogates and frailty. In summary, we used data from NHANES (National Health and Nutrition Examination Survey) 1999-2018 to study the association between different insulin substitutes and the occurrence of frailty. This may provide new insights for clinical treatment and prevention.

2 Materials and methods

2.1 Data source and study population

This study was based on data from the NHANES 1999-2018 and included 5247 participants aged 20 years and older. NHANES is a large, multistage, probability sampling national representative health survey conducted by the National Center for Health Statistics (NCHS), aimed at assessing the health and nutritional status of the non-institutionalized population in the United States. The participant selection process is shown in Figure 1. Exclusion criteria included: 1. Missing modules required for calculating METS-IR, HOMA-IR, TyG, and frailty scores; 2. Participants missing other covariate modules; 3. Remove participants with a weight of 0.



2.2 Frailty assessment

In our study, the construction of FI follows a series of specific criteria proposed by Searle (12). The FI index is based on the accumulation of defects involving health defects that are not only prevalent but also typically worsen with age, covering multiple physiological and psychological systems of individuals, and at least 80% of health defects are recorded in participants. FI is a continuous scoring system that calculates the number of acquired deficits in multiple life domains of individuals and divides it by the total number of potential deficits to obtain. These deficits include cognitive function, dependency on daily activities, depressive symptoms, comorbidities, hospital utilization rate, overall health status, physical function, anthropometry (e.g., BMI), and laboratory test results. Each deficit is scored based on its potential impact on individual function, typically ranging from 0 to 1. By referring to previous studies (13, 14), based on the score of FI, we set a threshold of 0.21, defining individuals as frail when their score reaches or exceeds this value, and non-frail when it is below this value. (More details are shown in Supplementary Table 1).

2.3 Explanatory variables

The surrogate indexes of IR in this study include HOMA-IR, TyG, and METS-IR. These IR surrogates are derived from blood samples taken after an overnight fast, collecting data on total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, fasting blood glucose, and insulin. The specific calculation formulas are as follows:

$$\begin{split} HOMA - IR &= \frac{fasting \ glucose \ (mmol/L) \times fasting \ insulin \ (\mu U/mL)}{22.5} \\ TyG &= ln \ (\frac{fasting \ triglycerides \ (mg/dL) \times fasting \ glucose \ (mg/dL)}{2}) \\ \\ METS - IR &= \frac{ln \ (2 \times fasting \ glucose \ (mg/dL) + fasting \ triglycerides \ (mg/dL)) \times body \ mass \ index \ (kg/m^2)}{ln \ (high - density \ lipoprotein \ cholesterol \ (mg/dL))} \end{split}$$

2.4 Definitions of covariates

This study included multiple covariates to analyze their potential effects on the main variables comprehensively. These covariates include age, sex, race (Non-Hispanic Black, Non-Hispanic White, Other/Multiracial, Mexican American, Other Hispanic), alcohol use (Never, Former, Mild, Moderate, Heavy), diet quality, total energy intake, physical activity, smoking status (Never, Former, Now), income level (Poor and Not poor), marital status (Never married, Married/Living with Partner, Widowed/ Divorced/Separated), and education attainment (Less than 9th grade, 9-11th Grade, High school grad/GED, Some college or AA degree, College graduate or above).

2.5 Statistical analysis

In this study, we considered the complex, multistage sampling design used by NHANES. Following official guidelines, we incorporated sample weights, stratification, and clustering into all statistical analyses, adhering to NHANES's analysis and reporting recommendations. Baseline characteristics of participants were classified according to their frailty status. For continuous variables, the means and 95% confidence intervals (CIs) were reported. For categorical variables, percentages and 95% CIs were used. Differences between groups were analyzed using the Wilcoxon rank-sum test for continuous variables and the chi-square test with Rao & Scott's second-order correction for categorical variables, which better handles the complexities of the sample design.

We used weighted logistic regression analysis to evaluate the linear association between METS-IR, HOMA-IR, TyG, and frailty, expressing the strength of associations with odds ratios (ORs) and 95% CIs. We constructed four models: Model 1 was unadjusted, Model 2 was adjusted for age, sex, and race (key factors in NHANES's design), and Model 3 was adjusted for sex, smoking status, and education level. Variables included in Model 3 were if their inclusion or exclusion caused a change in the regression coefficient for the primary variable (X) by more than 10%. Model 4 was adjusted for all considered covariates, including age, sex, race, alcohol use, education level, smoking status, diet quality, total energy intake, physical activity, income level, and marital status.

Additionally, METS-IR, HOMA-IR, and TyG were divided into quintiles. Weighted logistic regression was used to assess the association between each quintile and frailty, with trend tests conducted to evaluate consistent changes across index levels. We further analyzed potential nonlinear relationships between these IR surrogates and frailty using restricted cubic spline analysis, adjusting for all covariates and evaluating nonlinear relationships through likelihood ratio tests.

We performed subgroup analyses to explore potential factors influencing the associations between METS-IR, HOMA-IR, TyG, and frailty, considering age, sex, race, alcohol use, education level, smoking status, income level, and marital status. A two-tailed p-value < 0.05 was deemed statistically significant, and all analyses were conducted using R software version 4.3.1.

2.6 Ethics approval and consent to participate

This study adhered to the ethical standards of the Helsinki Declaration and its amendments or equivalent standards. The data used was sourced from the NHANES survey, which was approved by the NCHS Ethics Review Board. As this research involved secondary analysis of the NHANES database and complied with STROBE guidelines, no additional ethical approval was required. For detailed NHANES methodology and ethical standards, visit the CDC and NCHS websites: https://www.cdc.gov/nchs/ nhanes/irba98.htm.

3 Results

3.1 General characteristics of participants

As shown in Table 1, our study included 5,247 participants. Comparing frail and non-frail groups revealed no significant difference in mean age (both groups averaged 59 years). Frail individuals were more likely to be female, have poorer diet quality, lower energy intake and physical activity levels, higher prevalence of alcohol use and smoking, lower income and education levels, and were more likely to be widowed, divorced, or separated.

TABLE 1 General characteristics of participants.

	Frailty (1	N= 5247)					
Characteristic	No, N = 3874 ¹²	Yes, N = 1373 ¹²	P Value ³				
Age, years	59 [58, 59]	59 [58, 60]	0.6				
Diet quality (HEI-2015)	53 [52, 53]	49 [48, 50]	<0.001				
Total energy, kcal	2,117 [2,076, 2,158]	1,939 [1,877, 2,001]	<0.001				
Physical activity (MET × min/week)	3,114 [2,860, 3,369]	2,556 [2,266, 2,845]	<0.001				
Sex, %			<0.001				
Male	52 [50, 54]	40 [37, 44]					
Female	48 [46, 50]	60 [56, 63]					
Race, %			<0.001				
Non-hispanic black	7.1 [6.1, 8.4]	12 [9.9, 14]					
Non-hispanic white	81 [78, 83]	73 [69, 77]					
Other/multiracial	5.1 [4.2, 6.1]	5.9 [4.4, 7.9]					
Mexican American	3.9 [3.2, 4.7]	4.1 [3.2, 5.2]					
Other hispanic	3.3 [2.7, 4.0]	5.0 [3.5, 7.3]					
Alcohol use, %			<0.001				
Never	11 [9.4, 12]	9.9 [8.1, 12]					
Former	16 [15, 17]	27 [23, 30]					
Mild	45 [43, 48]	34 [30, 38]					
Moderate	14 [13, 16]	12 [10, 15]					
Heavy	14 [12, 15]	17 [14, 20]					
Income level, %			<0.001				
Poor	9.3 [8.0, 11]	24 [21, 28]					
Not poor	91 [89, 92]	76 [72, 79]					
Smoke status, %			<0.001				
Never	47 [45, 49]	36 [33, 39]					
Former	36 [34, 38]	35 [32, 39]					

TABLE 1 Continued

			1
	Frailty (N	N= 5247)	
Characteristic	No, N = 3874 ¹²	Yes, N = 1373 ¹²	P Value ³
Now	17 [16, 19]	29 [26, 32]	
Education attainment, %			<0.001
Less than 9th grade	4.2 [3.6, 4.8]	8.0 [6.5, 9.9]	
9-11th Grade	9.1 [8.0, 10]	15 [13, 18]	
High school grad/GED	24 [22, 27]	31 [28, 34]	
Some college or AA degree	31 [29, 34]	31 [28, 35]	
College graduate or above	31 [28, 34]	14 [12, 17]	
Marital status, %			<0.001
Never married	10 [8.9, 12]	8.3 [6.5, 11]	
Married/Living with Partner	69 [66, 71]	58 [54, 62]	
Widowed/ Divorced/ Separated	21 [20, 23]	33 [30, 37]	

¹Mean; %.

²CI, Confidence Interval.

 $^3 \rm Wilcoxon$ rank-sum test for complex survey samples; chi-squared test with Rao & Scott's second-order correction.

P value <0.05 is considered to have statistical significance and has been highlighted in bold.

3.2 Association between different IR surrogates and frailty

Using weighted multivariable logistic regression, we assessed the relationship between METS-IR, HOMA-IR, TyG, and frailty risk, as presented in Table 2. Both METS-IR and TyG showed significant positive associations with frailty risk across all models. In Model 4, which adjusted for all covariates, the Odds Ratio (OR) for TyG was 1.413 (95% CI: 1.202, 1.661), and for METS-IR was 1.036 (95% CI: 1.028, 1.044). HOMA-IR showed significant positive associations in Models 1 and 2, but these were not statistically significant in Models 3 and 4 after adjusting for additional covariates.

We divided these indices into quintiles to better compare the associations between METS-IR, HOMA-IR, TyG, and frailty. In Model 4, the highest quintile (Q5) for METS-IR had an OR of 2.960 (95% CI: 2.219, 3.949); for HOMA-IR, the OR was 2.522 (95% CI: 1.927, 3.301). Notably, HOMA-IR and TyG in the second quintile (Q2) showed a non-significant negative association with frailty, suggesting a potential nonlinear relationship.

3.3 Trend tests of association between different IR surrogates and frailty

We divided METS-IR, HOMA-IR, and TyG into quintiles and conducted trend tests. Results in Figure 2 show a clear trend effect

(Continued)

between these IR surrogates and frailty (P for trend < 0.05). Compared to the Q1 group, the risk of frailty rises as the levels of these indices increase.

3.4 Restricted Cubic Spline analysis of the association between different IR surrogates and frailty

We performed a weighted RCS analysis with adjustments for all relevant covariates to better fit the relationship between METS-IR, HOMA-IR, TyG, and frailty risk. The results in Figure 3 indicate that the relationship between METS-IR and frailty risk is likely linear (P-Nonlinear > 0.05). On the other hand, HOMA-IR and TyG have U-shaped relationships with frailty risk (P-Nonlinear < 0.05). As the levels of HOMA-IR and TyG increase, frailty risk first decreases, but after surpassing a threshold, the risk increases. This is consistent with the findings presented in Table 2; Figure 2.

3.5 Subgroup analysis of the relationship between different IR surrogates and frailty

Subgroup analyses explored the impact of different variables on the associations between METS-IR, HOMA-IR, TyG, and frailty

TABLE 2 Association between different IR surrogates and frailty.

risk. Detailed results are presented in Figure 4. TyG's association with frailty was robust across all subgroups (P for interaction > 0.05). In contrast, METS-IR's association with frailty was influenced by age, sex, alcohol use, and smoking status (P for interaction < 0.05), being more significant in older adults, females, and non-smokers. The HOMA-IR and frailty association was affected by sex, race, and smoking status, showing more significant associations in females and non-smokers.

4 Discussion

This study explored the relationship between different IR surrogates (METS-IR, HOMA-IR, and TyG) and frailty risk among 5,247 individuals from U.S. communities. The study revealed that despite the similar average age between the frail and non-frail groups, there were significant differences in gender distribution, dietary habits, lifestyle, and socioeconomic status in the frail group. Through weighted multivariate logistic regression analysis, high METS-IR, HOMA-IR, and TyG levels were significantly associated with frailty risk, with METS-IR in the highest quartile showing the strongest association with frailty.

RCS observed a possible linear relationship between METS-IR and frailty risk. At the same time, HOMA-IR and TyG showed a U-

	Model 1			Model 2			Model 3			Model 4			
Characteristic ¹	OR ²	95% Cl ²	p- value										
METS-IR	1.035	1.028, 1.042	<0.001	1.037	1.030, 1.044	<0.001	1.036	1.029, 1.043	<0.001	1.036	1.028, 1.044	<0.001	
HOMA-IR	1.047	1.001, 1.096	0.046	1.050	1.000, 1.101	0.050	1.050	0.9991, 1.104	0.054	1.044	0.9895, 1.102	0.11	
ТуG	1.467	1.279, 1.684	<0.001	1.574	1.358, 1.824	<0.001	1.409	1.218, 1.630	<0.001	1.413	1.202, 1.661	<0.001	
METS-IR Q5													
Q1	_	_		_	_		_	_		_	_		
Q2	0.9902	0.7450, 1.316	>0.9	1.057	0.7801, 1.432	0.7	1.060	0.7864, 1.428	0.7	1.032	0.7613, 1.400	0.8	
Q3	1.334	1.031, 1.727	0.028	1.432	1.095, 1.873	0.009	1.453	1.105, 1.909	0.008	1.411	1.066, 1.867	0.017	
Q4	1.827	1.371, 2.435	<0.001	2.066	1.525, 2.799	<0.001	1.928	1.423, 2.613	<0.001	1.865	1.361, 2.556	<0.001	
Q5	2.830	2.210, 3.624	<0.001	3.105	2.392, 4.030	<0.001	2.982	2.294, 3.874	<0.001	2.960	2.219, 3.949	<0.001	
HOMA-IR Q5												1	
Q1	_	-		_	_		_	_		_	_		
Q2	0.8631	0.6562, 1.135	0.3	0.8732	0.6582, 1.158	0.3	0.8827	0.6640, 1.173	0.4	0.9018	0.6781, 1.200	0.5	
Q3	1.033	0.8056, 1.325	0.8	1.050	0.8139, 1.355	0.7	1.080	0.8348, 1.396	0.6	1.055	0.8155, 1.364	0.7	

(Continued)

TABLE 2 Continued

		Model 1		Model 2				Model 3		Model 4		
Characteristic ¹	OR ²	95% Cl ²	p- value									
HOMA-IR Q5	•			•								
Q4	1.360	1.057, 1.751	0.017	1.388	1.079, 1.785	0.011	1.449	1.126, 1.863	0.004	1.431	1.098, 1.864	0.008
Q5	2.395	1.887, 3.039	<0.001	2.517	1.970, 3.215	<0.001	2.587	2.005, 3.338	<0.001	2.522	1.927, 3.301	<0.001
TyG Q5					1						1	
Q1	_	_		_	_		_	_		_	_	
Q2	1.086	0.7911, 1.491	0.6	1.110	0.8136, 1.514	0.5	1.029	0.7605, 1.392	0.9	0.9539	0.7096, 1.282	0.8
Q3	1.378	1.002, 1.896	0.049	1.442	1.041, 1.998	0.028	1.318	0.9571, 1.815	0.090	1.237	0.8996, 1.701	0.2
Q4	1.428	1.084, 1.881	0.012	1.521	1.152, 2.007	0.003	1.358	1.026, 1.799	0.033	1.280	0.9632, 1.701	0.088
Q5	2.193	1.686, 2.852	<0.001	2.485	1.892, 3.265	<0.001	1.989	1.513, 2.615	<0.001	1.969	1.483, 2.614	<0.001

¹Models: Model 1: Not adjusted; Model 2: Adjusted Age, Sex, Race; Model 3: Adjusted Sex, Smoke status, Education attainment; Model 4: Adjusted Age, Sex, Race, Alcohol use, Income level, Smoke status, Education attainment, MET, HEI, Total energy, Marital status.


²OR, Odds Ratio; CI, Confidence Interval.

P value <0.05 is considered to have statistical significance and has been highlighted in bold.

shaped nonlinear relationship with frailty risk. This finding suggests that different measures of insulin resistance might have distinct mechanisms in predicting frailty risk. Additionally, subgroup analysis further revealed that factors such as age, gender, race, alcohol use, and smoking status might influence these associations. Specifically, the association between METS-IR and frailty was more pronounced in older adults, women, and non-smokers. In contrast, HOMA-IR and frailty were more significant in women and non-smokers.

Numerous previous studies have noted the relationship between insulin resistance and frailty. A cross-sectional study involving 3,141 community-dwelling adults aged 69 to 74 years showed that HOMA-IR levels were positively associated with frailty risk; each standard deviation increase in HOMA-IR was associated with a 15% increase in frailty risk, and this positive association was also observed in prefrailty (15). Muscle wasting and decreased muscle mass are considered characteristics of frailty. Research by Christine et al. discovered that with increased HOMA-IR, weight, total lean mass, and appendicular lean mass decreased (16). Another study involving 2,403 Korean participants aged 70-84 found that men with high insulin resistance assessed by HOMA-IR had a significantly higher prevalence of sarcopenia compared to insulin-sensitive individuals (17). Other studies have also explained that increasing muscle mass can prevent IR. Ghachem et al. found that lean body mass is an independent predictor of IR, and increasing muscle mass can improve IR (18). Ahn et al. studied IR based on the TyG in the Korean population and found that groups with a lower skeletal muscle mass index had higher IR levels (19). Lower grip strength was also found to be associated with a high TyG, potentially related to the inactivation of insulin receptor substrates and loss of muscle mass (20). In a recent research, Yin Yuan et al. highlighted the relationship between the TyG and frailty, indicating that a long-term increase in the TyG is independently associated with an increased risk of frailty (7). This provides new evidence, besides HOMA-IR, directly reflecting the association between insulin resistance and frailty.


To further understand the association between different surrogate markers of insulin resistance and frailty, we adjusted for as many variables as possible in Model 4. The results showed that all different insulin resistance surrogates were correlated with frailty. Among them, METS-IR exhibited superior performance in predicting frailty risk when compared to TyG and HOMA-IR. One possible reason is that the METS-IR index takes into account not only fasting glucose and fasting triglycerides but also body mass index (BMI) and high-density lipoprotein cholesterol (HDL-C), making METS-IR more comprehensive in reflecting the complexity of insulin resistance. In contrast, HOMA-IR is based solely on fasting glucose and fasting insulin, while the TyG index considers only fasting triglycerides and fasting glucose. Several studies have found that indices including BMI-related factors often have higher predictive value, such as METS-IR and TyG-BMI (21). Consequently, METS-IR might more accurately capture the multidimensional features of metabolic syndrome, making it more effective in predicting the risk of frailty. This conclusion aligns with findings from other studies. For example, in evaluating the presence and severity of Coronary Artery Disease (CAD) (22), hyperuricemia, and the prevalence of periodontitis (23, 24), METS-IR demonstrated better predictive value among different noninsulin-based IR indexes23.



However, the mechanism linking IR to frailty is still unclear. Some studies suggest muscle metabolism is the main bridge between IR and aging. Most studies have observed that people with insulin resistance have lower lean body mass, higher fat mass, and often a decline in muscle mass (16, 20). This may be related to the weight loss and muscle strength decline commonly seen in frail populations (25). This may be associated with IR impairing muscle metabolism in frail individuals, which exacerbates the decline in lean body mass and muscle mass. Linda et al. observed improvements in muscle perfusion and vascular insulin resistance in diabetic patients treated with Empagliflozin (26). Another crossover study involving 13 young subjects found that interrupting sedentary behavior can lower postprandial glucose levels (27). The mechanism may involve muscle-releasing growth factors during physical activity, stimulating muscle growth, and improving insulin sensitivity. One can assume that reduced activity,

one of the main features of frailty, is an essential contributor to insulin resistance.

IR is also thought to have a bridging role in the development of inflammation and frailty. A cross-sectional study analyzing 529 adolescents aged 12 to 18 found that HOMA-IR was positively correlated with inflammation scores and negatively correlated with low muscle health (28). Unhealthy adolescents with high inflammatory biomarkers exhibited high HOMA-IR. Additionally, older adults have a reduced ability to process specific components of carbohydrates, which may contribute to oxidative stress or inflammatory responses in the body (29). The mechanisms involved may be related to the fact that insulin resistance increases oxidative stress and inflammatory reactions in the body. Linda et al. (26) and Mone et al. (30, 31) have had success in improving insulin resistance. They found that by using the SGLT2 (sodium-dependent glucose transporters 2) inhibitor engeletin



served to improve endothelial function and reduce mitochondrial oxidative stress in frail patients, epigenetically improving cognitive function and boosting muscle performance. In contrast, studies that attempted to use aspirin to simply inhibit inflammatory effects were observed to have no relief from the onset of frailty (32).

Given the points above, we boldly speculate that reduced activity due to multiple factors may be the initiating factor for frailty, a change that in turn triggers increased insulin resistance. Insulin resistance weakens muscle metabolism and may lead to adverse effects such as cognitive decline and oxidative stress,

	Frailty vs METS-IR			Frailty vs HOMA-IR			Frailty vs TyG		
Characteristic	OR (95% CI)		P-int	OR (95% CI)		P-int	OR (95% CI)		P-int
Age strata		1	< 0.001			0.181		1	0.184
Young to middle-aged	1.022(1.011,1.034)	H		1.021(0.959,1.087)			1.605(1.246,2.067)		
Older	1.045(1.035,1.055)	+++		1.064(1.019,1.112)	I		1.247(1.024,1.518)	•••	
Sex			0.021			0.003			0.132
Male	1.025(1.012,1.038)			1.014(0.988,1.041)	H-H		1.234(0.976,1.560)	(
Female	1.045(1.033,1.056)	H44		1.104(1.048,1.163)			1.643(1.311,2.059)	H	
Race			0.615			< 0.0001			0.643
Non-hispanic black	1.032(1.019,1.045)			1.062(0.999,1.129)	—		1.370(1.022,1.836)		
Non-hispanic white	1.040(1.030,1.051)	H++1		1.084(1.042,1.128)			1.418(1.151,1.747)	H+++	
Other/multiracial	1.049(1.001, 1.098)		•	1.211(1.061, 1.383)			1.536(0.802, 2.941)	+	-
Mexican american	1.028(1.004,1.053)			1.006(0.991,1.022)	101		1.675(1.195,2.349)		
Other hispanic	1.025(0.997,1.054)			1.001(0.991,1.011)	H		1.318(0.777,2.236)	H	
Alcohol use			0.017			0.257			0.096
Never	1.058(1.035,1.081)	—		1.089(0.986,1.203)	·		2.003(1.359,2.954)		-
Former	1.019(1.005,1.033)			1.028(0.998,1.060)	H		1.045(0.820,1.332)	H	
Mild	1.047(1.032,1.063)	H		1.021(0.958,1.089)			1.755(1.284,2.399)		
Moderate	1.058(1.035,1.081)			1.179(1.077,1.290)	—		1.649(1.152,2.360)		
Heavy	1.020(1.003,1.038)			1.051(0.995,1.110)			1.280(0.857,1.913)	+	
Income level			0.173			0.251			0.804
Poor	1.029(1.016,1.042)	H		1.017(0.987,1.049)	H		1.448(1.087,1.928)	H	
Not poor	1.038(1.029,1.048)	H+1		1.058(0.996,1.123)			1.400(1.156,1.697)	H+	
Smoke status			0.004			0.01			0.712
Never	1.051(1.038,1.064)	H		1.106(1.042,1.172)	—		1.580(1.171,2.133)	—	
Former	1.036(1.023,1.048)	H		1.008(0.991,1.026)	Here .		1.339(1.102,1.627)		
Now	1.018(1.005, 1.032)	H		1.056(1.006, 1.108)			1.319(0.984, 1.768)		
Education attainment			0.095			0.526			0.65
Less than 9th grade	1.047(1.020,1.075)			1.045(0.942,1.159)			1.466(0.960,2.238)		
9-11th Grade	1.026(1.008,1.046)			1.079(1.018,1.144)			1.388(0.914,2.110)		
High school grad/GED	1.031(1.018,1.044)	H		1.015(0.962,1.071)			1.545(1.123,2.124)		
Some college or AA degree	1.032(1.018,1.046)	H		1.028(0.919,1.149)			1.229(0.951,1.589)		
College graduate or above	1.060(1.037,1.083)			1.110(1.019,1.209)			1.592(1.012,2.503)		
Marital status			0.636			0.724			0.51
Never married	1.026(1.005, 1.048)			1.070(0.992, 1.154)			1.096(0.616, 1.947)		
Married/Living with Partner	1.035(1.024,1.045)	H		1.029(0.955,1.108)			1.432(1.137,1.802)		
Widowed/Divorced/Separated	1.039(1.027,1.052)		_	1.065(1.007,1.127)	ii		1.436(1.116,1.846)		_
Adjusted for:		1			1			1	
Age,Sex,Race,Alcohol use,Income lev									
Education attainment,MET,HEI,Tot: P-int: P for interaction	al energy,Marital status								

Subgroup analysis of the relationship between different IR surrogates and frailty.

creating a vicious cycle that significantly accelerates the process of frailty. Thus, IR plays a central role as an intermediary in this process, and it is closely linked to the precursors of frailty, such as reduced activity, muscle mass, and cognitive decline (33, 34), which are common pathologic features of frail populations.

Finally, we are the first to conduct a cross-sectional comparison of the relationship between different insulin resistance surrogates and frailty. Our research supports that improving insulin resistance can alleviate frailty. Some prospective studies have also found that insulin sensitizers can mitigate muscle loss in diabetic populations (35). Randomized trials have also found that metformin can somewhat reduce the risk of frailty in diabetic and prediabetic individuals (36–38). Moreover, increasing muscle mass is believed to be an early preventive measure against insulin resistance and type 2 diabetes (39). Therefore, early physical activity interventions are a cost-effective approach to reducing insulin resistance and the risk of frailty (5).

5 Strengths and limitations

The NHANES database offers a large sample size and a sampling design that more accurately reflects the frail population in U.S. communities. We accounted for various factors, such as age, gender, and comorbidities, in our analysis to reduce potential bias and error, thereby enhancing the robustness of our main findings. Furthermore, in clinical practice, it is challenging to gather data on young patients, leading to a lack of focus on this group in current clinical research. On the other hand, public databases collect data from the community, effectively bridging this gap, and this is considered one of the strengths of the NHANES public database. Our study found an association between insulin resistance and frailty, with METS-IR outperforming TyG and HOMA-IR as a predictor. However, like other cross-sectional studies, we cannot establish a causal relationship between insulin resistance and frailty. Thus, our results should be interpreted cautiously, and this methodological constraint may limit our conclusions.

Additionally, despite the broad representativeness of the NHANES database, there may still be some potential biases. Other important variables or factors, such as genetics, environment, lifestyle, regional populations, and cultural backgrounds, may not have been considered. These missing variables could influence the results. Despite these limitations, our findings remain reliable and could provide valuable scientific evidence for public health strategies and chronic disease management.

6 Conclusions

The research identified a linear association between METS-IR and frailty risk, whereas HOMA-IR and TyG displayed a U-shaped, nonlinear relationship pattern with the risk of frailty. Among the varying levels examined, the linkage between METS-IR and frailty was most pronounced in the top quintile. In summary, higher insulin resistance levels correlated with frailty.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes.

Ethics statement

The studies involving humans were approved by National Center for Health Statistics (NCHS) Ethics Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. As this research involved secondary analysis of the NHANES database and complied with STROBE guidelines, no additional ethical approval was required.

Author contributions

TL: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Data curation, Conceptualization. FG: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Data curation, Conceptualization. YC: Writing – review & editing, Validation, Supervision, Methodology. KH: Writing – review & editing, Validation, Supervision, Methodology.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2024.1439326/ full#supplementary-material

References

1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *journals gerontology Ser A Biol Sci Med Sci.* (2001) 56:M146–156. doi: 10.1093/gerona/56.3.m146

2. Brown JC, Harhay MO, Harhay MN. Appendicular lean mass and mortality among prefrail and frail older adults. *J nutrition Health Aging*. (2017) 21:342–5. doi: 10.1007/s12603-016-0753-7

3. Blodgett JM, Rockwood K, Theou O. Changes in the severity and lethality of agerelated health deficit accumulation in the USA between 1999 and 2018: a populationbased cohort study. *Lancet Healthy Longevity*. (2021) 2:e96–e104. doi: 10.1016/s2666-7568(20)30059-3

4. Liu Y, Han Y, Gao Y, Yao N, Wang Y, Wang F, et al. The association between oxidative balance score and frailty in adults across a wide age spectrum: NHANES 2007-2018. *Food Funct.* (2024) 15:5041–9. doi: 10.1039/d4fo00870g

5. Kidd T, Mold F, Jones C, Ream E, Grosvenor W, Sund-Levander M, et al. What are the most effective interventions to improve physical performance in pre-frail and frail adults? A systematic review of randomised control trials. *BMC geriatrics*. (2019) 19:184. doi: 10.1186/s12877-019-1196-x

6. Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. *Lancet* (*London England*). (2019) 394:1376–86. doi: 10.1016/s0140-6736(19)31785-4

7. Yuan Y, Chen S, Lin C, Huang X, Lin S, Huang F, et al. Association of triglycerideglucose index trajectory and frailty in urban older residents: evidence from the 10-year follow-up in a cohort study. *Cardiovasc Diabetol.* (2023) 22:264. doi: 10.1186/s12933-023-02002-3

8. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. *journals gerontology Ser A Biol Sci Med Sci.* (2007) 62:722–7. doi: 10.1093/gerona/ 62.7.722

9. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *J nutrition Health Aging*. (2012) 16:601–8. doi: 10.1007/s12603-012-0084-2

10. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet (London England). (2013) 381:752-62. doi: 10.1016/s0140-6736(12)62167-9

11. Hou XZ, Lv YF, Li YS, Wu Q, Lv YQ, Yang YT, et al. Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. *Cardiovasc Diabetol.* (2024) 23:86. doi: 10.1186/s12933-024-02173-7

12. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. *BMC geriatrics*. (2008) 8:24. doi: 10.1186/1471-2318-8-24

13. Guo HJ, Ye YL, Gao YF, Liu ZH. Age at first birth is associated with the likelihood of frailty in middle-aged and older women: A population-based analysis from NHANES 1999-2018. *Maturitas*. (2024) 181:107904. doi: 10.1016/j.maturitas.2023.107904

14. Hakeem FF, Bernabé E, Sabbah W. Association between oral health and frailty among American older adults. J Am Med Directors Assoc. (2021) 22:559–63.e552. doi: 10.1016/j.jamda.2020.07.023

15. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. *Arch Internal Med.* (2007) 167:635–41. doi: 10.1001/archinte.167.7.635

16. Lee CG, Boyko EJ, Strotmeyer ES, Lewis CE, Cawthon PM, et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. *J Am Geriatrics Soc.* (2011) 59:1217–24. doi: 10.1111/j.1532-5415.2011.03472.x

17. Kang S, Oh TJ, Cho BL, Park YS, Roh E, Kim HJ, et al. Sex differences in sarcopenia and frailty among community-dwelling Korean older adults with diabetes: The Korean Frailty and Aging Cohort Study. *J Diabetes Invest.* (2021) 12:155–64. doi: 10.1111/jdi.13348

18. Ghachem A, Lagacé JC, Brochu M, Dionne IJ. Fat-free mass and glucose homeostasis: is greater fat-free mass an independent predictor of insulin resistance? *Aging Clin Exp Res.* (2019) 31:447–54. doi: 10.1007/s40520-018-0993-y

19. Ahn SH, Lee JH, Lee JW. Inverse association between triglyceride glucose index and muscle mass in Korean adults: 2008-2011 KNHANES. *Lipids Health Dis.* (2020) 19:243. doi: 10.1186/s12944-020-01414-4

20. Zheng J, Zhang L, Jiang M. Lower handgrip strength levels probably precede triglyceride glucose index and associated with diabetes in men not in women. *J Diabetes Invest.* (2022) 13:148–55. doi: 10.1111/jdi.13626

21. Jayanama K, Theou O, Godin J, Mayo A, Cahill L, Rockwood K. Relationship of body mass index with frailty and all-cause mortality among middle-aged and older adults. *BMC Med.* (2022) 20:404. doi: 10.1186/s12916-022-02596-7

22. Wu Z, Cui H, Li W, Zhang Y, Liu L, Liu Z, et al. Comparison of three noninsulin-based insulin resistance indexes in predicting the presence and severity of coronary artery disease. *Front Cardiovasc Med.* (2022) 9:918359. doi: 10.3389/ fcvm.2022.918359

23. Lee YC, Lee JW, Kwon YJ. Comparison of the triglyceride glucose (TyG) index, triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, and metabolic score for insulin resistance (METS-IR) associated with periodontitis in Korean adults. *Ther Adv chronic Dis.* (2022) 13:20406223221122671. doi: 10.1177/20406223221122671

24. Wang H, Zhang J, Pu Y, Qin S, Liu H, Tian Y. Comparison of different insulin resistance surrogates to predict hyperuricemia among U.S. non-diabetic adults. *Front Endocrinol.* (2022) 13:1028167. doi: 10.3389/fendo.2022.1028167

25. Öztürk ZA, Türkbeyler İ H, Abiyev A, Kul S, Edizer B, Yakaryılmaz FD, et al, et al. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. *Internal Med J.* (2018) 48:973–81. doi: 10.1111/imj.13935

26. Jahn LA, Hartline LM, Nguyen T, Aylor K, Horton WB, Liu Z, et al. Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes. *Am J Physiol Endocrinol Metab.* (2024) 326:E258–e267. doi: 10.1152/ajpendo.00267.2023

27. Fletcher EA, Salmon J, McNaughton SA, Orellana L, Wadley GD, Bruce C, et al. Effects of breaking up sitting on adolescents' postprandial glucose after consuming meals varying in energy: a cross-over randomised trial. *J Sci Med sport*. (2018) 21:280–5. doi: 10.1016/j.jsams.2017.06.002

28. Agostinis-Sobrinho CA, Ramírez-Vélez R, García-Hermoso A, Moreira C, Lopes L, Oliveira-Santos J, et al. Low-grade inflammation and muscular fitness on insulin resistance in adolescents: Results from LabMed Physical Activity Study. *Pediatr Diabetes*. (2018) 19:429–35. doi: 10.1111/pedi.12607

29. Chuy V, Gentreau M, Artero S, Berticat C, Rigalleau V, Pérès K, et al. Simple carbohydrate intake and higher risk for physical frailty over 15 years in communitydwelling older adults. *journals gerontology Ser A Biol Sci Med Sci.* (2022) 77:10–8. doi: 10.1093/gerona/glab243

30. Mone P, Guerra G, Lombardi A, Illario M, Pansini A, Marro A, et al. Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease. *Pharmacol Res.* (2024) 200:107055. doi: 10.1016/j.phrs.2023.107055

31. Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. *Hypertension (Dallas Tex.: 1979).* (2022) 79:1633–43. doi: 10.1161/hypertensionaha. 122.19586

32. Espinoza SE, Woods RL, Ekram A, Ernst ME, Polekhina G, Wolfe R, et al. The effect of low-dose aspirin on frailty phenotype and frailty index in community-dwelling older adults in the ASPirin in reducing events in the elderly study. *journals gerontology Ser A Biol Sci Med Sci.* (2022) 77:2007–14. doi: 10.1093/gerona/glab340

33. Santulli G, Visco V, Ciccarelli M, Ferrante MNV, De Masi P, Pansini A, et al. Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study. *Cardiovasc Diabetol.* (2024) 23:125. doi: 10.1186/s12933-024-02218-x

34. Mone P, De Gennaro S, Moriello D, Frullone S, D'Amelio R, Ferrante MNV, et al. Insulin resistance drives cognitive impairment in hypertensive pre-diabetic frail elders: the CENTENNIAL study. *Eur J Prev Cardiol.* (2023) 30:1283–8. doi: 10.1093/eurjpc/zwad173

35. Lee CG, Boyko EJ, Barrett-Connor E, Miljkovic I, Hoffman AR, Everson-Rose S, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. *Diabetes Care*. (2011) 34:2381–6. doi: 10.2337/dc11-1032

36. Liu P, Pan Y, Song Y, Zhou Y, Zhang W, Li X, et al. Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes. *Eur J Med Res.* (2023) 28:65. doi: 10.1186/s40001-023-01017-6

37. Espinoza SE, Musi N, Wang CP, Michalek J, Orsak B, Romo T, et al. Rationale and study design of a randomized clinical trial of metformin to prevent frailty in older adults with prediabetes. *journals gerontology Ser A Biol Sci Med Sci.* (2020) 75:102–9. doi: 10.1093/gerona/glz078

38. Santulli G, Visco V, Varzideh F, Guerra G, Kansakar U, Gasperi M, et al. Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin. *Hypertension (Dallas Tex.: 1979).* (2024) 81:1637–43. doi: 10.1161/hypertensionaha.124.23087

39. Li S, Zhang R, Pan G, Zheng L, Li C. Handgrip strength is associated with insulin resistance and glucose metabolism in adolescents: Evidence from National Health and Nutrition Examination Survey 2011 to 2014. *Pediatr Diabetes*. (2018) 19:375–80. doi: 10.1111/pedi.12596